3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
28
Lymphoma, Follicular
17
Lymphoma, Non-Hodgkin
10
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Mantle-Cell
6
Lymphoma
5
Lymphoma, B-Cell, Marginal Zone
4
Lymphoma, B-Cell
3
Leukemia
3
Neoplasms
2
Bronchiolitis Obliterans Syndrome
2
Tumor Lysis Syndrome
1
Solid Tumors
1
Recurrence
1
Oncology Patients Receiving Chemotherapy
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Lymphoid
1
Leukemia, Hairy Cell
1
Indolent Non-Hodgkin's Lymphoma
1
Chromosome 17 deletion
1
Carcinoma, Non-Small-Cell Lung
1
B-cell Malignancies
1
Anemia
1
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
12
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Axitinib
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Erlotinib Hydrochloride
5
Docetaxel
5
Cyclophosphamide
5
Albumin-Bound Paclitaxel
5
Sorafenib
4
Radiation
4
Nivolumab
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Irinotecan
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
pralsetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
obinutuzumab
×
Clear all
No trials found.